
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow Inc. has demonstrated better-than-expected revenue performance in the U.S. for its FFRct product, indicating strong demand and adoption of its innovative non-invasive solutions for coronary artery disease. The company is positioned for significant revenue growth as it anticipates increasing adoption rates for both its FFR CT Analysis and Plaque Analysis technologies. Given these positive trends and the overall expansion of the elite medical technology sector, there is a favorable outlook for HeartFlow’s stock based on its potential for continued financial improvement.
Bears say
HeartFlow has faced substantial net losses since its establishment in 2007, reporting losses of $95.7 million in FY23 and $96.4 million in FY24, with expectations of further losses in the future, raising concerns about its ability to achieve profitability. The company's reliance on healthcare providers to adopt specific guidelines for referring patients may hinder the widespread implementation of its non-invasive diagnostic solutions, as such guidelines might not gain universal acceptance. Additionally, the risk of inadequate reimbursement from third-party payors, including government insurers, could adversely impact the adoption of the HeartFlow Platform, further complicating the company's financial outlook.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares